MedPath

Laparoscopic vs Open Total Gastrectomy for Gastric Cancer

Not Applicable
Recruiting
Conditions
Gastric Cancer
Interventions
Procedure: Total Gastrectomy
Registration Number
NCT05537129
Lead Sponsor
Fudan University
Brief Summary

The aim of the present study is to demonstrated the the safety and feasibility of laparoscopic total gastrectomy comparing with open total gastrectomy.

Detailed Description

Gastric cancer is most common cause of cancer-related deaths in the world. Laparoscopic distal gastrectomy has been demonstrated to be safe and effective compared with open distal gastrectomy. With an increase in incidences of proximal gastric cancer over the last decades, total gastrectomy has been prefered by surgeons, and laparoscopic total gastrectomy has become the alternative option. However, the safety and feasibility of laparoscopic total gastrectomy have yet to be proved completely.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
600
Inclusion Criteria
  1. histologically proven gastric adenocarcinoma in the upper or middle third of the stomach (by preoperative gastrofiberscopy)
  2. age between 20 and 80 years old
  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  4. clinical stage I-III (T1-4aN0-2M0) according to the 8th edition of the Americal Joint Committee on Cancer System (Clinical stage was determined based on the finding of gastrofiberscopy and abdominal computed tomography)
  5. scheduled for total gastrectomy with D2 lymphadenectomy, and possible for R0 surgery by this procedures (Lymphadenectomy is performed on the basis of the criteria of the Japanese
  6. written informed consent
  7. without preoperative chemotherapy and radiotherapy
Read More
Exclusion Criteria
  1. clinical stage T1-4N3M0 or T4bN0-3M0 according to the 8th edition of the Americal Joint Committee on Cancer System
  2. history of chemotherapy, radiotherapy, immunotherapy or target therapy
  3. perigastric lymphnode≥3cm
  4. received gastric surgery (i.e. gastrectomy or gastrojejunostomy)
  5. multiple primary tumors
  6. suffering from other serious diseases, including cardiovascular, respiratory, kidney, or liver disease, complicated by poorly controlled hypertension, diabetes, mental disorders or diseases.
  7. patients need emergency operation with complication of gastric cancer
  8. adhesion due to the previous intraabdominal surgery
  9. need for combined organ resection due to aggression of gastric cancer of other disease,
  10. vulnerable people who cannot communicate or are pregnant (or planning to be pregnant)
  11. currently participating or participated in other clinical trials in the last 6 months
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Open Total GastrectomyTotal Gastrectomy-
Laparoscopic Total GastrectomyTotal Gastrectomy-
Primary Outcome Measures
NameTimeMethod
3 year-DFS3 year

3 year-disease free survival

Secondary Outcome Measures
NameTimeMethod
morbidity and mortality rates30 days following surgeries

morbidity and mortality within 30 days following surgeries

3 year-OS3 year

3 year-overall survival

Trial Locations

Locations (1)

Fudan University Shanghai Cancer Center

🇨🇳

Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath